Camlin Fine Sciences: Monitoring Agency Report for Rights Issue Funds for Q4FY26
Camlin Fine Sciences submitted its final Monitoring Agency Report for the Rights Issue for the quarter ended March 31, 2026. The company confirmed no deviation in fund utilization. Total utilized funds were ₹22,468.39 Lakhs, primarily for debt repayment and general corporate purposes.
This is a routine compliance report for a past rights issue and does not indicate any new business developments, financial performance changes, or strategic shifts that would significantly impact the company's market position or stock price.
The announcement is a routine regulatory filing (Monitoring Agency Report) confirming no deviation in fund utilization from a past Rights Issue. It does not contain new financial performance data or significant future-oriented information, hence it is neutral.
Camlin Fine Sciences Limited has submitted the Monitoring Agency Report for the quarter ended March 31, 2026, concerning the utilization of funds raised through its Rights Issue. The report, prepared by India Ratings & Research Private Limited, was reviewed and approved by the Audit Committee on May 12, 2026, and the Board of Directors on May 15, 2026.
The company confirmed that there has been no deviation in the utilization of Issue proceeds from the objects stated in the Letter of Offer for the Rights Issue. The total issue size was ₹22,468.87 Lakhs, comprising 2,04,26,244 Equity Shares at ₹110 per share. Out of this, ₹22,468.39 Lakhs was utilized as of March 31, 2026, with 439 Rights Equity Shares kept in abeyance.
The utilization was primarily towards prepayment/repayment of certain borrowings (₹16,904.93 Lakhs) and general corporate purposes (₹5,494.22 Lakhs). The issue-related expenses amounted to ₹69.24 Lakhs. The report indicates that the entire utilized amount has been accounted for as per the objects of the issue, with no unutilized funds remaining as of the reporting date. This marks the final Monitoring Agency Report for this Rights Issue.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.